Structure via PubChem · Public domain (PubChem)
pibrentasvir
Sign in to savePibrentasvir is an NS5A inhibitor antiviral agent. In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C. It is sold by Abbvie.
Chemical data
- Formula
- C57H65F5N10O8
- Molecular weight
- 1113.2 g/mol
- IUPAC name
- methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2S)-1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate
- SMILES
- C[C@H]([C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C(=C3)F)[C@H]4CC[C@@H](N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)NC(=O)OC)OC
- InChIKey
- VJYSBPDEJWLKKJ-NLIMODCCSA-N
- XLogP
- 7.4
- Polar surface area
- 200 Ų
- H-bond donors
- 4
- H-bond acceptors
- 17
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2017
- Admin. routes
- oral
- Indications
- liver disease, hepatitis C virus infection, chronic hepatitis C virus infection, kidney disease
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 1112.490723
- Has use
- medication
Show 3 more facts
- isomeric SMILES
- CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(F)C(=C3)[C@H]4CC[C@@H](N4C5=CC(F)=C(N6CCC(CC6)C7=CC=C(F)C=C7)C(F)=C5)C8=CC9=C(NC(=N9)[C@@H]%10CCCN%10C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C=C8F
- chemical formula
- C₅₇H₆₅F₅N₁₀O₈
- canonical SMILES
- COC(=O)NC(C(=O)N1CCCC1c1nc2cc(C3CCC(c4cc5nc(C6CCCN6C(=O)C(NC(=O)OC)C(C)OC)[nH]c5cc4F)N3c3cc(F)c(N4CCC(c5ccc(F)cc5)CC4)c(F)c3)c(F)cc2[nH]1)C(C)OC
Sources (1)
via Wikidata · CC0
~2 min read
Encyclopedic overview
1 sectionsContents
- References
{{Infobox drug | drug_name = | IUPAC_name = Methyl {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)-1-piperidinyl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-threonyl]-2-pyrrolidinyl}-1H-benzimidazol-5-yl)-2-pyrrolidinyl]-6-fluoro-1H-benzimidazol-2-yl}-1-pyrrolidinyl]-3-methoxy-1-oxo-2-butanyl}carbamate | image = Pibrentasvir.svg | image_class = skin-invert-image | alt = | caption =
| pronounce = | tradename = Mavyret, Maviret (combination with glecaprevir) | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status =
Excerpted from Wikipedia’s “pibrentasvir” article, available under the CC BY-SA 4.0 licence.